Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Sebastian H. Scharf"'
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-11 (2022)
Abstract Drug resistance caused by mutations is a public health threat for existing and emerging viral diseases. A wealth of evidence about these mutations and their clinically associated phenotypes is scattered across the literature, but a comprehen
Externí odkaz:
https://doaj.org/article/c309742550b34f8fb0a789ce52afb184
Autor:
Xiao-Dong Wang, Yuncai Chen, Miriam Wolf, Klaus V. Wagner, Claudia Liebl, Sebastian H. Scharf, Daniela Harbich, Bianca Mayer, Wolfgang Wurst, Florian Holsboer, Jan M. Deussing, Tallie Z. Baram, Marianne B. Müller, Mathias V. Schmidt
Publikováno v:
Neurobiology of Disease, Vol 42, Iss 3, Pp 300-310 (2011)
Chronic stress evokes profound structural and molecular changes in the hippocampus, which may underlie spatial memory deficits. Corticotropin-releasing hormone (CRH) and CRH receptor 1 (CRHR1) mediate some of the rapid effects of stress on dendritic
Externí odkaz:
https://doaj.org/article/fbdb9b61308c47a4807c7303fdc0d0aa
Publikováno v:
PLoS ONE, Vol 6, Iss 2, p e16883 (2011)
BACKGROUND: Chronic stress has been found to be a major risk factor for various human pathologies. Stress activates the hypothalamic-pituitary-adrenal (HPA) axis, which is tightly regulated via, among others, the glucocorticoid receptor (GR). The act
Externí odkaz:
https://doaj.org/article/8e2cfc1518cd4bfdb232baf11e963bbc
Autor:
Florian Von Raison, Randall L. Carpenter, Will Spooren, George Apostol, Jacqueline N. Crawley, Eva Loth, Elizabeth Berry-Kravis, Lothar Lindemann, Vincent des Portes, Farah Hossain, Mark F. Bear, Randi J Hagerman, Sebastian H. Scharf, Baltazar Gomez-Mancilla, Paul P. Wang, David R Hessl, Sébastien Jacquemont, Fabrizio Gasparini, Aia E. Jønch, Aurore Curie
Publikováno v:
Other repository
Berry-Kravis, E M, Lindemann, L, Jønch, A E, Apostol, G, Bear, M F, Carpenter, R L, Crawley, J N, Curie, A, Des Portes, V, Hossain, F, Gasparini, F, Gomez-Mancilla, B, Hessl, D, Loth, E, Scharf, S H, Wang, P P, Von Raison, F, Hagerman, R, Spooren, W & Jacquemont, S 2018, ' Drug development for neurodevelopmental disorders : lessons learned from fragile X syndrome ', Nature Reviews. Drug Discovery, vol. 17, no. 4, pp. 280–299 . https://doi.org/10.1038/nrd.2017.221
Nature reviews. Drug discovery, vol 17, iss 4
Berry-Kravis, E M, Lindemann, L, Jønch, A E, Apostol, G, Bear, M F, Carpenter, R L, Crawley, J N, Curie, A, Des Portes, V, Hossain, F, Gasparini, F, Gomez-Mancilla, B, Hessl, D, Loth, E, Scharf, S H, Wang, P P, Von Raison, F, Hagerman, R, Spooren, W & Jacquemont, S 2018, ' Drug development for neurodevelopmental disorders : lessons learned from fragile X syndrome ', Nature Reviews. Drug Discovery, vol. 17, no. 4, pp. 280–299 . https://doi.org/10.1038/nrd.2017.221
Nature reviews. Drug discovery, vol 17, iss 4
Neurodevelopmental disorders such as fragile X syndrome (FXS) result in lifelong cognitive and behavioural deficits and represent a major public health burden. FXS is the most frequent monogenic form of intellectual disability and autism, and the und
Autor:
W. Pao, Bernhard Reis, Nadege Pelletier, Olivia Spleiss, Klas Hatje, John C. Reed, Michael A. Cannarile, David A. Schubert, Astrid Ruefli-Brasse, Sebastian H. Scharf, Chia Huey Ooi, Fabian Birzele
Publikováno v:
Cancer discovery. 8(4)
Checkpoint inhibitor therapy has been a breakthrough in cancer research, but only some patients with cancer derive substantial benefit. Although mechanisms underlying sensitivity and resistance to checkpoint inhibitors are being elucidated, the impor
Autor:
D. Harbich, Marianne B. Müller, Boadie W. Dunlop, Monika Rex-Haffner, Mathias V. Schmidt, David P. Herzog, Klaus V. Wagner, Peter Weber, Tania Carrillo-Roa, Helen S. Mayberg, Manfred Uhr, Christiana Labermaier, Inge Sillaber, Caleb A. Lareau, Sara Santarelli, Charles B. Nemeroff, Sebastian H. Scharf, W. Edward Craighead, Florian Holsboer, Elisabeth B. Binder
Publikováno v:
PLoS Biology
PLOS BIOLOGY
PLoS Biology, Vol 15, Iss 12, p e2002690 (2017)
PLoS biology, 15(12):e2002690
PLOS BIOLOGY
PLoS Biology, Vol 15, Iss 12, p e2002690 (2017)
PLoS biology, 15(12):e2002690
Response to antidepressant treatment in major depressive disorder (MDD) cannot be predicted currently, leading to uncertainty in medication selection, increasing costs, and prolonged suffering for many patients. Despite tremendous efforts in identify
Autor:
Marianne B. Müller, Felix Hausch, Elisabeth B. Binder, Florian Holsboer, Rainer Landgraf, Julia Brenndörfer, L. Czibere, Peter Weber, Mathias V. Schmidt, Carina Quast, Christiana Labermaier, Andre Altmann, Jakob Hartmann, Sebastian H. Scharf, Christian Devigny, Janine Arloth, Manfred Uhr, Klaus V. Wagner, Christine Kohl, Regina Widner-Andrä, Kenneth A. Jones
Publikováno v:
Endocrinology. 155:2500-2510
Chronic stress is a risk factor for psychiatric disorders but does not necessarily lead to uniform long-term effects on mental health, suggesting modulating factors such as genetic predispositions. Here we address the question whether natural genetic
Publikováno v:
Neuropharmacology. 72:38-46
Exposure to chronic stress during developmental periods is a risk factor for a number of psychiatric disorders. While the direct effects of stress exposure have been studied extensively, little is known about the long-lasting effects and the interact
Autor:
Mathias V. Schmidt, Matthias Eder, C. Liebl, Marianne B. Müller, Jan M. Deussing, Klaus V. Wagner, Wolfgang Wurst, Sebastian H. Scharf, Xiao-Dong Wang, Jakob Hartmann, Florian Holsboer, Yun-Ai Su, Charilaos Avrabos, Claudia Kühne, Miriam Wolf
Publikováno v:
Nature reviews / Neuroscience 16(6), 706-713 (2013). doi:10.1038/nn.3395
Stress impairs cognition via corticotropin-releasing hormone receptor 1 (CRHR1), but the molecular link between abnormal CRHR1 signaling and stress-induced cognitive impairments remains unclear. We investigated whether the cell adhesion molecule nect
Autor:
Manfred Uhr, Mathias V. Schmidt, Florian Holsboer, Marianne B. Müller, Daria Marinescu, Jakob Hartmann, Christiana Labermaier, C. Liebl, Sebastian H. Scharf, Xiao-Dong Wang, Klaus V. Wagner
Publikováno v:
Neuropsychopharmacology. 37:2797-2808
Various clinical studies have identified FK506-binding protein 51 (FKBP51) as a target gene involved in the development of psychiatric disorders such as depression. Furthermore, FKBP51 has been shown to affect glucocorticoid receptor signaling by sen